Clinical Trial

Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)

Study acronym: GENSA
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2022 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The natural history of non-muscle-invasive bladder cancer is characterised by recurrence and progression. We compare the effectiveness of gemcitabine hydrochloride and epirubicin hydrochloride, in combination with continuous saline irrigation, as an immediate single intravesical instillation in the potential reduction of the disease recurrence as well as progression.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-06-25; most recent amendment 2022-01-25.
Status change: Not Yet Recruiting → Recruiting 2022-01-25
Trial Details
NCT Number NCT04947059
Lead Sponsor University of Thessaly
Conditions Bladder Cancer
Enrollment 180 participants
Start Date 2021-12-14
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2022-01-26